Chi-Med loss widens on R&D costs but revenues strong
This article was originally published in Scrip
Hutchison China MediTech (Chi-Med)'s net loss rose to $17.8 million last year from $17.2 million in calendar 2007, affected by higher R&D spending. Nevertheless, the company said the fundamentals of its business remained strong, with the China Healthcare division logging particularly good growth.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.